BioCryst Pharmaceuticals, Inc. (BCRX) holds floating shares of 79.28 million and 80.44 million outstanding shares. In terms of a technical look around BioCryst Pharmaceuticals, Inc. (BCRX) stock price comparison to its moving averages, shares of company spotted the move of -23.35% isolated from the 50-day moving average and derived -14.51% away from 20-day moving average in the most recent session. The stock price also has got the drift of -32.87% from the 200-day moving average.
The stock’s quarterly performance set out a shift of -25.18% and pick out performance of -5.96% over last twelve months. The company generated a return on equity (ROE) of -276.60%. A high ROE indicates successfully earning more assets and value for its shareholders off its reinvested earnings. A low ROE warns that the company is not generating a good return on its reinvested earnings. BioCryst Pharmaceuticals, Inc. (BCRX)’s RSI (Relative Strength Index) is 27.97. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions.
BioCryst Pharmaceuticals, Inc. (BCRX) stock marked a gap of -55.68% off its 52 week- peak price value and pointed turn of 9.33% from its 52 week-bottom price value. This price movement gives investors an idea of how much the stock price has moved in the last year and whether it is trading near the top, middle or bottom of the range. The “percentage off the 52-week high or low” refers to when a stock current price is relative to where it has traded over the last 52 weeks.
At the present time, shares of BioCryst Pharmaceuticals, Inc. (BCRX) are worth at $4.10. The stock built a change of 0.00% as of a recent closing trading date. It last trading capacity has been watched at 0.63 million shares and 1.55 million shares are explored as seeing the average capacity of last three months trading period. 0.40% shares have in possession of Insiders investors and Institutional investors maintain the ownership of 87.00% shares. The company achieved year to date performance of -35.23% and disseminated yield of -37.50% for the past six months.
BioCryst Pharmaceuticals, Inc. (BCRX) stock exposed a turn of -9.49% in most recent week and accomplished -26.39% performance over the last one month. The company showed volatility of 4.81% over the past week and moving out to look at the previous month volatility move, the stock is at 5.68%.
Analyst mean recommendation on a stock by the analyst community is at 2.40. Analyst rating score as outlined on Finviz rated on a 1 to 5 scale. 1 and 2 is equivalent to a buy rating, 3 a hold rating, and 4 and 5 a sell rating. Investors of this company earned a return of -44.40% on the assets it owns in past twelve month.